VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium - PubMed (original) (raw)
. 2001 Aug 30;20(38):5393-400.
doi: 10.1038/sj.onc.1204692.
Affiliations
- PMID: 11536052
- DOI: 10.1038/sj.onc.1204692
VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium
X Ma et al. Oncogene. 2001.
Abstract
Mutations in the von Hippel-Lindau (VHL) gene are frequently detected in human sporadic renal cell carcinoma (RCC). We analysed 102 Swedish RCCs for VHL mutations by PCR-SSCP and sequencing. In 47 patients (46.1%), 70 different mutations were found, and most of them represented novel variations of the VHL gene. Mutations in the VHL gene were found in 54% of clear cell renal cell carcinomas (CCRCC) and in 18% of chromophilic cancers but in no chromophobe cancers or oncocytomas (P=0.016). Three novel hotspot or founder mutations were detected in our study: four CCRCCs carried a missense mutation (glutamic acid to lysine) at codon 160 which is critical in the stabilization of the H1 helix of the alpha domain and the alpha-beta domain interface in the VHL protein. Five CCRCCs and one chromophilic RCC harbored a 15-nucleotide in-frame deletion (codons 41-45) at a duplex tandem repeat sequence site. Moreover, this deletion was in linkage disequilibrium with a C-->T transition in the promoter region. The frequency of linkage was 17 times more common than chance. Five patients with this linked mutation resided in the same hospital district and at least three of them showed the two sequence variants in the tumor-adjacent tissue. In 5/6 patients the wild-type allele was lost in the tumor samples, suggesting a causal role for the mutations in RCC. These linked mutations might be novel polymorphisms maintained in a relative isolated population. Multiple mutations in VHL were found in 17 tumors out of 47 tumors with the VHL mutation. A higher multiple mutation detected rate (33%) was observed in grade 3 CCRCCs than those in grade 1 (22%) and grade 2 (9%) (P=0.04). This is evidence on the association between VHL mutation and extent of nuclear atypia.
Similar articles
- VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Brauch H, Weirich G, Brieger J, Glavac D, Rödl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Störkel S, Rotter M, Masera A, Gugeler N, Decker HJ. Brauch H, et al. Cancer Res. 2000 Apr 1;60(7):1942-8. Cancer Res. 2000. PMID: 10766184 - Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
Gallou C, Joly D, Méjean A, Staroz F, Martin N, Tarlet G, Orfanelli MT, Bouvier R, Droz D, Chrétien Y, Maréchal JM, Richard S, Junien C, Béroud C. Gallou C, et al. Hum Mutat. 1999;13(6):464-75. doi: 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A. Hum Mutat. 1999. PMID: 10408776 - [Frequent somatic mutations of the von Hippel-Lindau tumor suppressor gene in primary sporadic human renal clear cell carcinomas].
Gong K, Zhang Z, Xin D. Gong K, et al. Zhonghua Yi Xue Za Zhi. 2001 Feb 10;81(3):142-4. Zhonghua Yi Xue Za Zhi. 2001. PMID: 11798864 Chinese. - Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B. Zbar B. Cancer Surv. 1995;25:219-32. Cancer Surv. 1995. PMID: 8718521 Review. - [Prevention of renal carcinoma: the nutri-genetic approach].
Junien C, Dupret JM, Gallou C, Longuemaux S, Richard S, Saquet C, Krishnamoorty R, Delomenie C, Droz D, Bouvier R, Chauveau D, Joly D, Grunfeld JP, Chretien Y, Mejean A, Beroud C. Junien C, et al. J Soc Biol. 2000;194(1):29-38. J Soc Biol. 2000. PMID: 11107547 Review. French.
Cited by
- Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Reuter CW, Morgan MA, Grünwald V, Herrmann TR, Burchardt M, Ganser A. Reuter CW, et al. World J Urol. 2007 Mar;25(1):59-72. doi: 10.1007/s00345-007-0152-0. Epub 2007 Mar 6. World J Urol. 2007. PMID: 17340158 Review. - Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.
Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE. Young AC, et al. Clin Cancer Res. 2009 Dec 15;15(24):7582-7592. doi: 10.1158/1078-0432.CCR-09-2131. Clin Cancer Res. 2009. PMID: 19996202 Free PMC article. - The genetic differences between types 1 and 2 in von Hippel-Lindau syndrome: comprehensive meta-analysis.
Azimi F, Naseripour M, Aghajani A, Kasraei H, Chaibakhsh S. Azimi F, et al. BMC Ophthalmol. 2024 Aug 13;24(1):343. doi: 10.1186/s12886-024-03597-1. BMC Ophthalmol. 2024. PMID: 39138406 Free PMC article. - Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma.
Wu Y, Tan C, Weng WW, Deng Y, Zhang QY, Yang XQ, Gan HL, Wang T, Zhang PP, Xu MD, Wang YQ, Wang CF. Wu Y, et al. Am J Cancer Res. 2016 Jan 15;6(2):285-99. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186403 Free PMC article. - Alterations in VHL as potential biomarkers in renal-cell carcinoma.
Gossage L, Eisen T. Gossage L, et al. Nat Rev Clin Oncol. 2010 May;7(5):277-88. doi: 10.1038/nrclinonc.2010.42. Epub 2010 Apr 6. Nat Rev Clin Oncol. 2010. PMID: 20368728 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical